Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe most common side effects of Mounjaro (tirzepatide) are gastrointestinal — nausea, diarrhoea, constipation, indigestion and vomiting — and they tend to be most noticeable in the first few days after starting or after a dose increase, often easing within a week or two. Mounjaro is a prescription-only medicine, and a prescriber will review your full health picture before it's suitable for you. This page covers what the evidence shows, which symptoms need urgent attention, and what most people actually experience day to day. For background on tirzepatide and how it works, that overview fills in the mechanism behind the side-effect profile.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
In the SURMOUNT-1 trial (the main phase 3 study that supported Mounjaro's UK licence) gastrointestinal symptoms were by far the most common reason participants reported feeling unwell. Nausea led the list, followed by diarrhoea, vomiting, constipation, indigestion and burping. Fatigue and headache were also reported. The NHS patient information page for tirzepatide groups these as common effects, meaning they occur in more than one in a hundred people.
The good news is that timing matters. Most people find the GI symptoms are worst in the 24 to 72 hours after an injection, particularly following a dose step-up, and that they fade considerably once the body has had a few weeks to adjust. Eating smaller meals, staying well hydrated and avoiding very fatty or spicy food in the first few days of each new dose can help. Your prescriber and the Patient Information Leaflet that comes with your pen cover this in more detail, practical adjustments are worth trying before assuming a dose isn't right for you.
Injection-site reactions (redness, mild swelling, itching at the spot) affect some users too. Rotating between the abdomen, thigh and upper arm helps reduce these. One thing worth knowing: the pen delivers the same medicine regardless of which of those sites you choose, so pick whichever feels most comfortable to rotate around. If you want a fuller picture of Mounjaro side affects, that page covers the full profile in detail before your next dose day. If you're finding dizziness is an issue, that's covered separately and is worth reading before your next dose day.
Dizziness and light-headedness appear in trial data but often get less attention than the GI symptoms. They can result from reduced food intake, dehydration from an unsettled stomach, or simply from the medicine's effects on gastric motility. Standing up slowly, keeping fluid intake steady and making sure you're eating enough protein each day all make a practical difference.
There's also what some patients describe as a shift in their relationship with food, reduced appetite that goes further than expected, sometimes to the point where eating feels like an effort. This can occasionally lead to inadequate protein or calorie intake. It's worth flagging to your prescriber if meals become a real struggle rather than just smaller. A registered dietitian can help if that pattern persists.
Hair thinning is reported by some people on significant calorie restriction during rapid weight loss and is generally considered a consequence of the weight loss itself rather than the medicine directly. It tends to be temporary. If you're managing treatment alongside other medicines or have questions about how Mounjaro interacts with oral contraceptives specifically, NHS guidance notes that the pill's absorption may be reduced during the first four weeks of treatment and for four weeks after each dose increase, using an additional barrier method during those windows is advised. Your prescriber will cover this at consultation.
For a broader look at how Mounjaro affects the body beyond the side-effect list, that page covers the mechanism in plain language.
Most side effects are uncomfortable rather than dangerous. But some symptoms should not be waited out, and it's important to know which ones they are before you start treatment.
In January 2026, the MHRA issued a Drug Safety Update specifically on GLP-1 medicines and acute pancreatitis. The warning: severe, persistent stomach pain that spreads to the back (with or without vomiting) should prompt you to stop the injection and seek urgent medical help the same day. Acute pancreatitis is uncommon, but it can be serious and it is a recognised risk with this class of medicine.
Other symptoms that need prompt medical attention include signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing, rapid heartbeat), gallbladder problems (sharp pain in the upper right abdomen, particularly after eating), and symptoms of significant dehydration from persistent vomiting or diarrhoea, dizziness, very dark urine, not passing urine for several hours. If you feel unwell and are unsure whether it's urgent, call 111 or speak to your GP. Don't wait for your next scheduled prescription review.
If you ever want to report a suspected side effect directly to the regulator, the MHRA's Yellow Card scheme is open to patients as well as clinicians, the link is yellowcard.mhra.gov.uk. Reports from real-world users strengthen post-market safety monitoring for medicines like Mounjaro, which still carries a Black Triangle (▼) denoting additional MHRA surveillance.
For the majority of people, they improve. The titration schedule (starting at 2.5mg and stepping up gradually under prescriber guidance) exists precisely to reduce the severity of early GI effects. Rushing through dose increases tends to make symptoms worse; the schedule is paced for a reason.
By the time most people reach their maintenance dose, the nausea and digestive disruption that were noticeable in the first couple of months have typically reduced to something much more manageable or disappeared altogether. Some people find certain effects (a dampened appetite, some sensitivity to fatty food) persist, but at a level they consider tolerable given the overall benefit. That trade-off is personal, and it's the kind of conversation worth having with your prescriber at each review rather than adjusting things yourself.
If you're thinking about whether Mounjaro is right for your situation, the Mounjaro overview page covers eligibility, how it's licensed and what the clinical trial results showed. On questions about specific side effects and how to manage them, that page goes into further practical detail. And if you're curious about other weight-loss treatment options alongside tirzepatide, that overview sets out what's currently available through a regulated UK service. One note on timing: if you're planning to start treatment and want same-day dispatch, orders placed before 12pm on a working day move fastest, something worth factoring in around bank holidays or busy periods.
If you've read through the side-effect profile and want a prescriber to assess whether Mounjaro is clinically suitable for you, start your free consultation and a GPhC-registered prescriber will review your answers the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.